We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.55% | 9.15 | 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | 1,054,095 | 12:15:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/4/2018 08:08 | The announcement regarding the new platform was presumably what RG was referring to at the recent Proactive one2one meeting (see report: ). I look forward to hearing more about it. I have gone for a for a few shares in the placing, don't know allocation yet, but it wouldn't surprised me to see some scale back. The accompanying open offer will presumably be on a one for tewnty basis, so I suspect that it is likely to be fully taken up | timbo003 | |
18/4/2018 07:59 | We knew they wanted funds? so a shrewd move to get on with it in current uncertain climate.I reckon placing will be completed soon.Albeit the 29% discount demanded by the institutions. Encouraging technology transfer news from Nottingham university. | j777j | |
18/4/2018 07:47 | TF - New arrangements mean nothing for a share price climb. This Company has to generate cash not burn it. | terror | |
18/4/2018 07:42 | Morning Terror, I'm more interested in the new arrangements with Nottingham Uni and this 3rd IP platform ? Do you understand it ? But it's hardly 'left field' is it, so want ELSE is coming ? Don't panic . . . | torquayfan | |
18/4/2018 07:41 | Terror, the guy is a menace. I hope he now clears off and never returns. | tosh 123 | |
18/4/2018 07:40 | Ineptico.... WRONG once again... and the ASTUTE once again " called it 100% right ". you, are a numbnut. | tosh 123 | |
18/4/2018 07:21 | How a company with such a fantastic product can raise cash at a massive discount to the share price must sicken the MFF sheep. Nana - what do you make of a 12p Open Offer when you are predicting 10 times that as a starter? The Company continues to massively disappoint. | terror | |
18/4/2018 07:13 | PRICE CRASH coming. Seems the ASTUTE were right again | terror | |
17/4/2018 19:03 | Thanks for that goosed - vaccines, vaccines and vaccines then. Of course Ira Mellman VP of Genentech and member of Lindy Durrant's Grand Challenge team:) | bermudashorts | |
17/4/2018 15:00 | insane'n'co I don't think I am alone in observing YOUR 'mental stress, and now thinking that = Somewhere,there is 'waiting',a 'sanctuary' in a 'special ward'...with YOUR name on it. | the real lozan | |
17/4/2018 14:51 | yes but the others did not know your plan ......... | inanaco | |
17/4/2018 14:38 | No - It was BoB i asked = because his input is more reliable than YOUR B S It was BoB who DID respond = in an 'adult manner', providing USEFUL info It was BoB = Who received 8 reccs and thanks from others . It is YOUR 'wounded EGO' that folks see other posters 'chatting / discussing SCLP matters' WITHOUT YOU... that has REALLY = Got YOUR Goat And Driven YOU to 'have a PATHETIC go' at BoB again today on the 'inferior BB'. . My 14996 posts STANDS YOUR runaway EGO CAN't stand the thought that = YOU are IGNORED YOU might like to try * SITTING* on it...Instead of *TALKING* through it | the real lozan | |
17/4/2018 14:20 | really ? Its Bob that got played to provide you with ammo ... | inanaco | |
16/4/2018 16:27 | insane'n'co - YOU are pathetic | the real lozan | |
16/4/2018 16:23 | No Problem, leave him with Bob .. | inanaco | |
16/4/2018 15:48 | Some good stuff coming out of AACR : | gooosed | |
16/4/2018 15:23 | Inan . . . . ''Not being critical T/F .. do what ever you want, but isolating him (Lozan), looks to be the only game left after all, nobody else is engaging.'' Go on then - you too. ATB | torquayfan | |
16/4/2018 15:06 | Hey Bermuda. Thanks for that great post and no nasty stuff of course. I ride my Bike from Chantaburi to Laem Sing by the sea - a Friend (USA) but an English Prof. - we meet for coffee. Yesterday - we chatted Scancell. He can identify. Having lost one side of his face and whole scalp to skin cancer - had a massive graft from his leg. After 5 years he is cancer free. He knows Keith Flaherty and chatted to him then at Massachusets General often around the time of his many ops. A few years ago chatting to KF he was offered trials. But atm he is cancer free. He knows KF is a top Man too. I'm just saying - small world - coincidental only - but don't underestimate what's going on HG wise ! (Holy Grail of Prof. Lindy that is). He's a lucky one. Have some respect Guys in your chats . . . Maybe others can be OK too . . . | torquayfan | |
16/4/2018 13:42 | Lozan, SCIB1 We know that Keith Flaherty, who is director of Termeer Center at Massachusetts General Hospital and Assoc. Professor at Harvard Medical School will be principle investigator and other study investigators include Jennifer Wargo (M D Anderson), Paul Chapman (Memorial Sloan Kettering), Omid Hamid (USC Keck). So this trial will clearly be US based. I'm not sure whether they'll also open a centre in the UK or not. As for no. of patients and trial design, the last information we had was that there will be a small safety run in with 6 patients and then the trial will be expanded to 25 patients. If those patients produce 12 or more RECIST responses then the combination will be taken further. I assume that your reason for asking is funding. As far as this trial goes, the manufacture of the vaccine, all pre-clinical work and IND submission is already funded so you're looking at just the cost of a 25 patient trial. Important to note though that my understanding is that the cost of Keytruda will be covered as this is in effect the SOC treatment for these patients. MODI-1 Scancell have mentioned obtaining clinical trial approval from the MHRA so I assume this trial will be run only in the UK. Again based only on last info., there will be a dose escalation study with 3 cohorts of 6 patients each. At the end of the dose escalation the study will be expanded with a further 10 patients. So a total of 28 patients. The cost of manufacture has already been covered. SCIB2 Goodness knows and am looking forward to finding out! Of course this will be funded entirely by Cancer Research UK. We won't know for sure until the IND and CTA applications are approved and things may change. Recent developments here and the increasingly high profile reputation of Prof. Durrant both in Europe and the US will no doubt provide a comfort blanket to potential investors and I'm sure Scancell will raise the funds they require when the time is right for them. | bermudashorts | |
16/4/2018 13:40 | Inanaco Don't really understand your post but that's not overly unusual but I'm glad you feel you've "won"! Interesting you keep mentioning £1 and £3. You seem to be criticising me for agreeing with you (for a few weeks)! I don't remember you ever withdrawing your predictions, so don't try and tar me with the same brush. I withdrew any suggestion that I was looking for either amount in the short/med term by changing my stance on the company, which you then continued to attempt to rubbish for nearly five years! Anyway, thanks for the response, guess we're back where we started first thing today! Now (with our new found collaborators) we could possibly well be back on track for such levels, that's why you'll have noticed I've become more positive towards the share price Fingers crossed. That's me done on this, ATB | oldnotwise | |
16/4/2018 13:21 | insane'n'co - YOU obviously - 'Have a screw loose' Probably the reason why, with YOUR BUY, BUY, BUY SCAM = 'The wheels have fallen off' | the real lozan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions